Communiqués Silence Therapeutics plc OTC Markets

Actions

SLNCF

GB00B9GTXM62

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 19:22:40 24/08/2026			Varia. 5j.	Varia. 1 janv.
4,000 ^USD	-27,27%		-.--%	+100,00%

07/09	Echec d'un essai de phase III pour Novartis
31/08	Les actions européennes cotées aux États-Unis sous forme d'ADR s'inscrivent en légère baisse lors de la séance de lundi	MT

Communiqués

02/09	Silence Therapeutics to Participate in Three September Investor Conferences	BU
17/08	Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs	AQ
14/08	Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs	BU
12/08	Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering	BU
10/08	Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares	BU
10/08	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile	BU
10/08	Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results	BU
09/08	Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera	BU
11/06	Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera	BU
27/05	Silence Therapeutics to Participate in Jefferies Global Healthcare Conference	BU
12/05	Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference	BU
07/05	Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results	BU
05/03	Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results	BU
15/12	Silence Therapeutics Announces Leadership Changes	BU
12/11	Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference	BU
06/11	Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights	BU
24/10/25	Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera	AQ
23/10/25	Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)	BU
02/09/25	Silence Therapeutics to Participate in September Investor Conferences	BU
07/08/25	Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights	BU
12/06/25	Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera	BU
08/05/25	Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights	BU
06/05/25	Silence Therapeutics Welcomes Tim McInerney to Board of Directors	BU
05/03/25	Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference	BU
27/02/25	Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update	BU